In 2025, prominent Indian pharmaceutical companies like Sun Pharma, Zydus Lifesciences, and Syngene continued their US expansion through strategic acquisitions and investments, such as Sun Pharma’s purchase of Checkpoint Therapeutics for oncology assets, Zydus Lifesciences’ acquisition of a US manufacturing facility for biologics, and Syngene’s first US biologics manufacturing site. These strategic moves, including acquisitions of specific companies, product lines, and manufacturing capabilities, allowed Indian firms to hedge against market volatility, improve health security, diversify production, and gain market access in the United States.
Key Investments By Indian Pharmaceutical Companies In The U.S. In 2025
Below mentioned chart shows a comprehensive list of confirmed acquisitions (completed or announced) by Indian pharmaceutical companies involving U.S.-based companies, assets, or facilities in 2025, up to August 31, 2025. This includes full company takeovers, manufacturing sites, and regulatory assets like ANDAs (Abbreviated New Drug Applications) approved by the U.S. FDA. We have focused on deals with clear U.S. ties, excluding plans or unconfirmed discussions (e.g., BDR Pharmaceuticals’ $100M expansion intent). The general trends show Indian firms leveraging cash reserves for US expansion amid regulatory shifts and biosimilar demand.
Drivers Of These Acquisitions
(a) Market Uncertainty: Acquisitions allow Indian companies to hedge against potential market uncertainties and regulatory challenges in their home market.
(b) Health Security: Expanding manufacturing facilities and diversifying production locations within the US contribute to health security.
(c) Market Access And R&D: These strategic moves enhance market access and align with the Indian government’s goal of strengthening research and development capabilities for new drugs.
(d) Consolidation: The industry saw consolidation, with companies merging to gain scale and efficiency.
(e) Strategic Focus: Many deals target biosimilars, generics, and manufacturing to capitalize on US market growth (e.g., oncology, immunotherapy) while hedging against domestic risks. Indian firms hold record cash piles (~Rs 10,200 crore increase in FY25 alone), fueling this spree.
(f) Potential Risks: U.S. policy changes (e.g., executive orders on generics) could spotlight India’s role in global supply chains. However, these acquisitions strengthen resilience.
Scale And Impact
Total deal value from listed acquisitions exceeds $1.8 billion. No major Torrent Pharma US deals in 2025; focus was on Indian acquisitions like JB Chemicals. There seems to be an “overseas acquisition spree” by firms like Intas and Zydus. In essence, 2025 marked a strategic period where Indian pharmaceutical firms strengthened their foothold in the US by acquiring specific assets and capabilities, rather than solely focusing on traditional export models.